A breast cancer vaccine is showing promise in early clinical trials. Initially, the vaccine was tested in people with triple-negative breast cancer (TNBC) who were at high risk for recurrence. Now the vaccine is being tested to lower breast cancer risk among people with an inherited mutation in BRCA1, BRCA2 or PALB2. It is also being tested in people with triple-negative breast cancer who are at high risk for recurrence and are taking the immunotherapy drug Keytruda (pembrolizumab) after completing chemotherapy. (Posted 1/31/24)
For people who are diagnosed with TNBC or have residual disease after chemotherapy and are taking Keytruda:
For people who have never been diagnosed with breast cancer who have a BRCA1, BRCA2 or PALB2 mutation:
FORCE offers many peer support programs for people with inherited mutations.
The following organizations have resources related to breast cancer.
The following are breast cancer screening or prevention studies enrolling people at high risk for breast cancer.
NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. This study is testing a new vaccine to lower the risk of breast cancer in high-risk women with an inherited mutation in BRCA1, BRCA2 or PALB2.
Additional risk-management clinical trials for people at high risk for breast cancer may be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.